Abstract Background An increased incidence of pneumococcal infection triggered by influenza infection has been reported. Objective To examine the effectiveness of the additive inoculation of influenza vaccine (I-V) and 23-valent pneumococcal vaccine (P-V) 
Introduction

The Global Initiative for Chronic Obstructive Lung Diseases (GOLD) 2006 Guideline has recommend the influenza vaccine (I-V) inoculation as evidence A and the 23-valent pneumococcal polysaccharide vaccine (P-V) inoculation as
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(PAF) receptor in the airways is elevated and Streptococcus pneumoniae binds to the receptor and then penetrates cells (3) . In addition, the number of IL-10 that acts to suppress the defensive ability increases and facilitates the penetration of pathogenic bacteria into the human body (4 
Results
Except for seven patients who could not be observed for 2 years because they died of diseases other than respiratory infections within 2 years after P-V inoculation, 98 patients were evaluated in this study. The number of bacterial respiratory infections per patient decreased significantly (p= T a b l e 2 . B a c t e r i a l Re s p i r a t o r y I n f e c t i o n s
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Discussion
Among the pathogenic microorganisms of communityacquired pneumonia and pneumonia that develops at nursing homes today, Streptococcus pneumoniae accounts for 25 to 40% of them in Japan and the most predominant pathogen of pneumonia (6) . This trend is observed worldwide (12, 13) 
. Furthermore, Streptococcus pneumoniae has presented markedly high acquisition rates of drug resistance in Asian countries compared to Europe and the United States. Namely, the penicillin-resistant strains including penicillin intermediately-resistant Streptococcus pneumoniae (PISP) and penicillin-resistant Streptococcus pneumoniae (PRSP),
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The increased number of bacterial strains against which treatment with antibiotics is ineffective has emerged as an important issue related to pneumococcal infections. Therefore, the prevention of pneumococcal infections is essential in the clinical setting. The GOLD 2006 Guideline has recommended the inoculation of I-V as evidence A and has evaluated the inoculation of P-V as evidence B (1). In patients with complications by diabetes mellitus, coronary artery disease, congenital heart failure, chronic pulmonary disease, and other dis-
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T h e n u mb e r o f b a c t e r i a l r e s p i r a t o r y i n f e c t i o n s , n u mb e r o f h o s p i t a l i z a t i o n s d u e t o b a c t e r i a l r e s p i r a t o r y i n f e c t i o n s , a n d l e n g t h o f h o s p i t a l s t a y d u r i n g i n f l ue n z a s e a s o n s a n d i n p a t i e n t s o n h o me o x y g e n t h e r a p y b e f o r e a n d a f t e r P -V i no c u l a t i o n a r e s h o wn . n s : n o t s i g n i f i c a n t eases, the inoculation of P-V alone has been reported to have a pneumococcal infection-preventive effect (15) (16) (17) (18) a preventive effect on the deterioration of pneumonia severity (19, 20) and a lowering effect on mortality from pneumonia in the elderly (21) . Furthermore, the WHO (22) has indicated that the inoculation of P-V is effective not only for pneumococcal pneumonia but also for other types of pneumonia. However, the effect of P-V has been reported to be limited to only invasive pneumococcal pneumonia (23) , and negative data on its effect have also been reported (24) (25) (26) .
Although the additive inoculation of I-V and P-V has never been recommended by the GOLD guidelines, we consider that the inoculation is of primordial importance in obtaining a better secondary bacterial infection-preventive effect. Since Streptococcus pneumoniae binds to the PAF receptor on cell surfaces and penetrates cells, the incidence of pneumococcal infection when contracting influenza infection increases. Therefore, the additive inoculation of I-V and P-V has been reported to lower the incidence of hospitalizations due to diseases, e.g., pneumococcal pneumonia and other types of pneumonia (5) , the mortality from pneumonia (27) , febrile duration, and length of hospital stay (28) 
. Hence, we examined the lower respiratory infection-preventive effect of the additive inoculation of I-V and P-V in Japanese patients with chronic respiratory disease who underwent regular medical treatment on an ambulatory basis. This study also revealed decreases in the total number of bacterial infections and in the number of hospitalizations after P-V inoculation, indicating an additive effect of I-V and P-V. Regarding the influenza season, there were a greater number of patients with influenza infection after P-V inoculation. However, no secondary infection after contracting influenza infection was observed in patients before and after
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P-V inoculation. Nor was there found an increase in the number of bacterial infections during the influenza season.
As shown in Fig. 3 With the limited sample size in this study, the additive inoculation of I-V and P-V showed a lower respiratory tract infection-preventive effect that generated a statistically significant difference presumably because this study included as variables prevalence (39) , clinical stage as assessed by forced expiratory volume in one second (40) (41) (42) , and length of hospital stay (43) 
Conclusions
The additive inoculation of I-V and P-V in Japanese patients with chronic respiratory disease prevented the development of bacterial respiratory infections and warrants further research in a greater number of patients with respiratory disease.
